Document Detail


Individually determined postpartum magnesium sulfate therapy with clinical parameters to safely and cost-effectively shorten treatment for pre-eclampsia.
MedLine Citation:
PMID:  9790377     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The purpose of this study was to investigate the safety of treating pre-eclampsia with magnesium sulfate, with clinical determinants used for drug discontinuation. STUDY DESIGN: One hundred sixty-eight patients were enrolled. After delivery, women with mild pre-eclampsia received a minimum of 6 hours of intravenous magnesium sulfate, whereas women with severe pre-eclampsia received a minimum of 12 hours. Magnesium sulfate was discontinued in the absence of clinical symptoms associated with spontaneous diuresis, minimal protein by urinary dipstick, and satisfaction of predetermined blood pressure criteria. RESULTS: Patients with mild pre-eclampsia required significantly less magnesium sulfate (mean 9.5 +/- 4.2 hours) than did those with severe pre-eclampsia alone (mean 16 +/- 5.9 hours); pre-eclampsia superimposed on chronic hypertension (mean 16 +/- 5.8 hours); or hemolysis, elevated liver enzyme, and low platelet count syndrome (mean 20 +/- 6.7 hours). With this protocol there was no eclampsia, and recovery room time was reduced by 50%. CONCLUSION: Individual determination of postpartum magnesium sulfate therapy for pre-eclampsia appears to be a safe approach that carries minimal risk of eclampsia.
Authors:
M H Ascarelli; V Johnson; W L May; R W Martin; J N Martin
Related Documents :
3766437 - Lack of an association between calcium intake and blood pressure in postmenopausal women.
7450567 - Evaluation of the supine pressor test.
15983237 - Parental longevity and 7-year changes in blood pressures in adult offspring.
6538697 - Gastro-oesophageal reflux in pregnancy. altered function of the barrier to reflux in as...
7500627 - Ankle systolic blood pressure following sub-maximal and maximal exercises in healthy yo...
18376937 - Effect of solvent on absorption spectra of all-trans-beta-carotene under high pressure.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of obstetrics and gynecology     Volume:  179     ISSN:  0002-9378     ISO Abbreviation:  Am. J. Obstet. Gynecol.     Publication Date:  1998 Oct 
Date Detail:
Created Date:  1998-11-10     Completed Date:  1998-11-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370476     Medline TA:  Am J Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  952-6     Citation Subset:  AIM; IM    
Affiliation:
Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson 39216-4505, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Cesarean Section
Chronic Disease
Cost-Benefit Analysis
Delivery, Obstetric
Female
Gestational Age
Hemolysis
Humans
Hypertension / complications
Liver / enzymology
Magnesium Sulfate / administration & dosage,  therapeutic use*
Postpartum Period
Pre-Eclampsia / drug therapy*,  economics
Pregnancy
Thrombocytopenia
Time Factors
Chemical
Reg. No./Substance:
7487-88-9/Magnesium Sulfate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Deve...
Next Document:  Success rate of cytogenetic analysis at the time of second-trimester dilation and evacuation.